Publications

• Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody production.
  J Thromb Haemost Volume: 23 Page(s): 440 - 457
  02/01/2025 Authors: York ES; Dratch BD; Ito J; Horwitz SM; Emamian S; Ambarian JA; Gill S; Jones J; Chonat S; Lollar P
• Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.
  N Engl J Med Volume: 392 Page(s): 450 - 457
  01/30/2025 Authors: Srivastava A; Abraham A; Aboobacker F; Singh G; Geevar T; Kulkarni U; Selvarajan S; Korula A; Dave RG; Shankar M
• Structural basis for inhibition of coagulation factor VIII reveals a shared antigenic hotspot on the C1 domain.
  J Thromb Haemost Volume: 22 Page(s): 2449 - 2459
  09/01/2024 Authors: Childers KC; Cowper B; Vaughan JD; McGill JR; Davulcu O; Lollar P; Doering CB; Coxon CH; Spiegel PC
• Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size.
  J Thromb Haemost Volume: 22 Page(s): 2052 - 2058
  07/01/2024 Authors: Liang Q; Parker ET; Dean G; Karpen MS; Wu Y; Wang X; Di Paola J; Maier CL; Meeks SL; Lollar P
• Human gut microbes express functionally distinct endoglycosidases to metabolize the same N-glycan substrate.
  Nat Commun Volume: 15 Page(s): 5123
  06/15/2024 Authors: Sastre DE; Sultana N; V A S Navarro M; Huliciak M; Du J; Cifuente JO; Flowers M; Liu X; Lollar P; Trastoy B
• Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module.
  Blood Volume: 143 Page(s): 1992 - 2004
  05/09/2024 Authors: Arce NA; Markham-Lee Z; Liang Q; Najmudin S; Legan ER; Dean G; Su AJ; Wilson MS; Sidonio RF; Lollar P
• Structure of coagulation factor VIII bound to a patient-derived anti-C1 domain antibody inhibitor.
  Blood Volume: 142 Page(s): 197 - 201
  07/13/2023 Authors: Childers KC; Avery NG; Estrada Alamo KA; Davulcu O; Haynes RM; Lollar P; Doering CB; Coxon CH; Spiegel PC
• pH-dependent conformation of multimeric von Willebrand factor.
  Blood Adv Volume: 7 Page(s): 2554 - 2557
  06/13/2023 Authors: Smith IW; Parker ET; Lollar P
• Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
  Nat Commun Volume: 14 Page(s): 2853
  05/18/2023 Authors: Gupta A; Kao KS; Yamin R; Oren DA; Goldgur Y; Du J; Lollar P; Sundberg EJ; Ravetch JV
• Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain.
  Blood Volume: 141 Page(s): 1221 - 1232
  03/09/2023 Authors: Legan ER; Liu Y; Arce NA; Parker ET; Lollar P; Zhang XF; Li R
• Mechanism of glycoform specificity and protection against antibody dependent enhancement by an anti-afucosylated IgG nanobody.
  bioRxiv
  01/24/2023 Authors: Gupta A; Kao K; Yamin R; Oren DA; Goldgur Y; Du J; Lollar P; Sundberg EJ; Ravetch JV
• Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner.
  Front Immunol Volume: 14 Page(s): 1233356
  01/01/2023 Authors: Batsuli G; Ito J; York ES; Cox C; Baldwin W; Gill S; Lollar P; Meeks SL
• Subunit Flexibility of Multimeric von Willebrand Factor/Factor VIII Complexes.
  ACS Omega Volume: 7 Page(s): 31183 - 31196
  09/06/2022 Authors: Parker ET; Haberichter SL; Lollar P
• SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa.
  Blood Adv Volume: 6 Page(s): 3240 - 3254
  06/14/2022 Authors: Childers KC; Peters SC; Lollar P; Spencer HT; Doering CB; Spiegel PC
• Nonhuman glycans can regulate anti-factor VIII antibody formation in mice.
  Blood Volume: 139 Page(s): 1312 - 1317
  03/03/2022 Authors: Arthur CM; Zerra PE; Shin S; Wang J; Song X; Doering CB; Lollar P; Meeks S; Stowell SR
• Desialylation of O-glycans activates von Willebrand factor by destabilizing its autoinhibitory module.
  J Thromb Haemost Volume: 20 Page(s): 196 - 207
  01/01/2022 Authors: Voos KM; Cao W; Arce NA; Legan ER; Wang Y; Shajahan A; Azadi P; Lollar P; Zhang XF; Li R
• Measurement of the Translational Diffusion Coefficient and Hydrodynamic Radius of Proteins by Dynamic Light Scattering.
  Bio Protoc Volume: 11 Page(s): e4195
  10/20/2021 Authors: Parker ET; Lollar P
• Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction.
  Blood Adv Volume: 5 Page(s): 3333 - 3343
  09/14/2021 Authors: Knight KA; Coyle CW; Radford CE; Parker ET; Fedanov A; Shields JM; Szlam F; Purchel A; Chen M; Denning G
• Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor.
  Blood Volume: 137 Page(s): 2981 - 2986
  05/27/2021 Authors: Gish JS; Jarvis L; Childers KC; Peters SC; Garrels CS; Smith IW; Spencer HT; Doering CB; Lollar P; Spiegel PC
• Conformation of the von Willebrand factor/factor VIII complex in quasi-static flow.
  J Biol Chem Volume: 296 Page(s): 100420
  01/01/2021 Authors: Parker ET; Lollar P
• Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.
  Front Immunol Volume: 12 Page(s): 697602
  01/01/2021 Authors: Ronayne EK; Peters SC; Gish JS; Wilson C; Spencer HT; Doering CB; Lollar P; Spiegel PC; Childers KC
• The 3.2 structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.
  J Thromb Haemost Volume: 18 Page(s): 57 - 69
  01/01/2020 Authors: Smith IW; d'Aquino AE; Coyle CW; Fedanov A; Parker ET; Denning G; Spencer HT; Lollar P; Doering CB; Spiegel PC
• Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII.
  Front Immunol Volume: 11 Page(s): 150
  01/01/2020 Authors: Zakas PM; Healey JF; Smith IW; Lillicrap D; Lollar P
• Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens.
  PLoS One Volume: 15 Page(s): e0233866
  01/01/2020 Authors: Li SW; Wright M; Healey JF; Hutchinson JM; O'Rourke S; Mesa KA; Lollar P; Berman PW
• Epitope Dependent Augmentation of the Immune Response in Hemophilia. Mice Immunized with Factor VIII/Antibody Immune Complexes
  Volume: 134
  11/13/2019 Authors: Batsuli G; Patel SR; Cox C; Baldwin WH; Lollar JS; Meeks SL
• STRUCTURAL EVIDENCE OF AN ANTI-FACTOR VIII C1 DOMAIN ANTIBODY BOUND TO B DOMAIN-DELETED FVIII
  Volume: 104 Page(s): 20 - 20
  09/09/2019 Authors: Gish J; Peters S; Childers K; Smith I; Parker E; Healey J; Spencer HT; Doering C; Lollar P; Spiegel PC
• FVIII-specific CD4 T cell proliferation requires multiple previous exposures to FVIII
  Volume: 25 Page(s): 76 - 76
  07/01/2019 Authors: Zerra P; Patel S; Baldwin W; Healey J; Parker E; Cox C; Lollar P; Stowell S; Meeks S
• Structural basis of transcriptional regulation by the HigA antitoxin.
  Mol Microbiol Volume: 111 Page(s): 1449 - 1462
  06/01/2019 Authors: Schureck MA; Meisner J; Hoffer ED; Wang D; Onuoha N; Ei Cho S; Lollar P; Dunham CM
• Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
  Hum Gene Ther Volume: 29 Page(s): 1183 - 1201
  10/01/2018 Authors: Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
• Delimiting the autoinhibitory module of von Willebrand factor.
  J Thromb Haemost Volume: 16 Page(s): 2097 - 2105
  10/01/2018 Authors: Deng W; Voos KM; Colucci JK; Legan ER; Ortlund EA; Lollar P; Li R
• Anti-C1 domain antibodies that accelerate factorVIII clearance contribute to antibody pathogenicity in a murine hemophiliaA model.
  J Thromb Haemost Volume: 16 Page(s): 1779 - 1788
  09/01/2018 Authors: Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
• Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.
  J Thromb Haemost Volume: 16 Page(s): 303 - 315
  02/01/2018 Authors: Healey JF; Parker ET; Lollar P
• Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.
  Blood Volume: 130 Page(s): 2559 - 2568
  12/07/2017 Authors: Zerra PE; Cox C; Baldwin WH; Patel SR; Arthur CM; Lollar P; Meeks SL; Stowell SR
• The Impact of Specific Factor VIII Domains on Uptake By Dendritic Cells
  Volume: 130
  12/07/2017 Authors: Batsuli GM; Meeks SL; Lollar JS
• A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor.
  J Thromb Haemost Volume: 15 Page(s): 1867 - 1877
  09/01/2017 Authors: Deng W; Wang Y; Druzak SA; Healey JF; Syed AK; Lollar P; Li R
• Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.
  Blood Volume: 130 Page(s): 808 - 816
  08/10/2017 Authors: Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Jacquemin M; Krause M; Tiede A; Schwabe D; Lollar P
• Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics.
  Haemophilia Volume: 23 Page(s): 292 - 299
  03/01/2017 Authors: Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Donfield SM; Astermark J; Berntorp E; Lollar P; Schwabe D
• Factor VIII C2 Domain Epitopes Recognized By Classical and Non-Classical Anti-C2 Domain Monoclonal Antibodies Help Mediate FVIII Uptake By Dendritic Cells
  Volume: 128
  12/02/2016 Authors: Batsuli G; Baldwin WH; Healey JF; Parker ET; Cox C; Lollar P; Meeks SL
• Characterization of Factor VIII Immune Complexes By Analytical Ultracentrifugation
  Volume: 128
  12/02/2016 Authors: Lollar P; Parker ET; Healey JF; Doering CB
• A Short N-Terminal Fragment in Front of the A1 Domain of Von Willebrand Factor Prevents the A1 from Binding the Platelet By Masking a Region Clustered By Type 2B VWD Mutations
  Volume: 128
  12/02/2016 Authors: Deng W; Wang Y; Lollar P; Li R
• High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
  Blood Volume: 128 Page(s): 2055 - 2067
  10/20/2016 Authors: Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Knigs C; Li R
• Fill 'er up? Fill what up?
  Blood Volume: 128 Page(s): 156 - 157
  07/14/2016 Authors: Lollar P
• Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile.
  Haemophilia Volume: 22 Page(s): 308 - 317
  03/01/2016 Authors: Lillicrap D; Schiviz A; Apostol C; Wojciechowski P; Horling F; Lai CK; Piskernik C; Hoellriegl W; Lollar P
• Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
  J Thromb Haemost Volume: 14 Page(s): 346 - 355
  02/01/2016 Authors: Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL
• Anti-C1 Domain Antibodies Are Pathogenic in a Murine Tail Snip Model Despite Low Inhibitor Titers
  Volume: 126
  12/03/2015 Authors: Batsuli G; Healey J; Parker E; Baldwin WH; Nguyen B; Lollar P; Meeks SL
• An Immunodominant B Cell Epitope is Present on the C1 Domain of FVIII
  HAEMOPHILIA Volume: 21 Page(s): E260 - E261
  05/01/2015 Authors: Batsuli G; Healey J; Baldwin W; Parker E; Lollar P; Meeks S
• Epitope mapping via selection of anti-FVIII antibody-specific phage-presented peptide ligands that mimic the antibody binding sites.
  Thromb Haemost Volume: 113 Page(s): 396 - 405
  02/01/2015 Authors: Kahle J; Orlowski A; Stichel D; Becker-Peters K; Kabiri A; Healey JF; Brettschneider K; Naumann A; Scherger AK; Lollar P
• Decreasing the Humoral Response to Factor VIII By Targeted Deletion of Factor VIII - Specific B Cells
  Volume: 124
  12/06/2014 Authors: Markovitz RC; Healey JF; Baldwin WH; Parker ET; Meeks SL; Lollar P
• Anti-Factor VIII C1 Domain Antibodies Are Present in the Plasmas of Patients with Hemophilia and Inhibitors
  Volume: 124
  12/06/2014 Authors: Batsuli G; Cox C; Healey JF; Lollar P; Meeks SL
• Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII.
  Haemophilia Volume: 20 Page(s): 723 - 731
  09/01/2014 Authors: Grushin K; Miller J; Dalm D; Parker ET; Healey JF; Lollar P; Stoilova-McPhie S
• Philip J. Fay (1953-2014).
  J Thromb Haemost Volume: 12 Page(s): 1576
  09/01/2014 Authors: Krishnaswamy S; Lollar P
• High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.
  Blood Volume: 123 Page(s): 2732 - 2739
  04/24/2014 Authors: Nguyen P-CT; Lewis KB; Ettinger RA; Schuman JT; Lin JC; Healey JF; Meeks SL; Lollar P; Pratt KP
• Reconciliation of classical and reacted-site probability approaches to allowance for ligand multivalence in binding studies.
  J Mol Recognit Volume: 27 Page(s): 73 - 81
  02/01/2014 Authors: Lollar P; Winzor DJ
• Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.
  Blood Volume: 122 Page(s): 4270 - 4278
  12/19/2013 Authors: Walter JD; Werther RA; Brison CM; Cragerud RK; Healey JF; Meeks SL; Lollar P; Spiegel PC
• Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.
  J Biol Chem Volume: 288 Page(s): 9905 - 9914
  04/05/2013 Authors: Walter JD; Werther RA; Polozova MS; Pohlman J; Healey JF; Meeks SL; Lollar P; Spiegel PC
• The diversity of the immune response to the A2 domain of human factor VIII.
  Blood Volume: 121 Page(s): 2785 - 2795
  04/04/2013 Authors: Markovitz RC; Healey JF; Parker ET; Meeks SL; Lollar P
• A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
  Blood Volume: 120 Page(s): 2512 - 2520
  09/20/2012 Authors: Meeks SL; Cox CL; Healey JF; Parker ET; Doshi BS; Gangadharan B; Barrow RT; Lollar P
• The Structural and Functional Diversity of the Humoral Immune Response to the A2 Domain of Human Factor VIII
  Volume: 118 Page(s): 977 - 978
  11/18/2011 Authors: Markovitz R; Lollar JPS; Healey JF; Parker ET; Meeks S
• High-Resolution Mapping of B-Cell Epitopes on the Factor VIII C2 Domain Using Surface Plasmon Resonance
  Volume: 118 Page(s): 95 - 95
  11/18/2011 Authors: Phuong-Cac N; Lewis KB; Schuman JT; Meeks SL; Healey JF; Lollar P; Pratt KP
• Factor VIII Structure, Not Activity, Is the Primary Determinant of Immunogenicity in Hemophilia A and Combined Hemophilia A/Von Willebrand Disease Mice
  Volume: 118 Page(s): 535 - 536
  11/18/2011 Authors: Meeks SL; Cox C; Healey JF; Parker ET; Gangadharan B; Barrow RT; Lollar JPS
• Hepatic clearance of B-domain less factor viii does not require its prior activation to factor VIIIA
  JOURNAL OF THROMBOSIS AND HAEMOSTASIS Volume: 9 Page(s): 729 - 730
  07/01/2011 Authors: Strickland D; Migliorini M; Parker ET; Lollar P
• Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.
  Blood Volume: 117 Page(s): 3190 - 3198
  03/17/2011 Authors: Summers RJ; Meeks SL; Healey JF; Brown HC; Parker ET; Kempton CL; Doering CB; Lollar P
• Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.
  Mol Ther Volume: 19 Page(s): 302 - 309
  02/01/2011 Authors: Spencer HT; Denning G; Gautney RE; Dropulic B; Roy AJ; Baranyi L; Gangadharan B; Parker ET; Lollar P; Doering CB
• N1922S Mutation In the Factor VIII A3 Domain Produces a Rate-Limiting, Domain-Specific Folding Defect Leading to Hyposecretion of a Functional Protein.
  Volume: 116 Page(s): 910 - 910
  11/19/2010 Authors: Summers RJ; Meeks SL; Healey JF; Brown HC; Parker ET; Doering C; Kempton CL; Lollar JPS
• The Diversity of the Immune Response to the A2 Domain of Human Factor VIII In a Murine Hemophilia A Model.
  Volume: 116 Page(s): 915 - 915
  11/19/2010 Authors: Healey JF; Lollar JPS; Parker ET
• Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation.
  J Thromb Haemost Volume: 8 Page(s): 1037 - 1043
  05/01/2010 Authors: Gershom ES; Sutherland MR; Lollar P; Pryzdial ELG
• A Subset of High Titer Acquired Hemophilia Patients May Benefit from Treatment with High Dose Factor VIII
  Volume: 114 Page(s): 1349 - 1349
  11/20/2009 Authors: Meeks S; Healey JF; Parker ET; Lollar P
• Cooperative Interaction Between Classical and Non-Classical Factor VIIII C2 Domain Antibody Epitopes
  Volume: 114 Page(s): 95 - 96
  11/20/2009 Authors: Antun AG; Meeks SL; Healey JF; Parker ET; Lollar P
• Comparative Decay Rates of Human, Rhesus Macaque, Cynomolgus, and Porcine Activated Factor VIII
  Volume: 114 Page(s): 1228 - 1228
  11/20/2009 Authors: Healey JF; Parker E; Lollar JPS
• Herpes Simplex Virus Initiates the Intrinsic Pathway of Coagulation
  Volume: 114 Page(s): 1231 - 1231
  11/20/2009 Authors: Gershom ES; Sutherland MR; Lollar P; Pryzdial EL
• Proteolytically Inactivatable Factor VIII is Less Immunogenic than Factor VIII in a Murine Hemophilia A Model
  Volume: 114 Page(s): 17 - 17
  11/20/2009 Authors: Meeks S; Parker ET; Dunn AL; Healey JF; Lollar P
• The immune response to factor VIII
  Volume: 7 Page(s): 36 - 36
  07/01/2009 Authors: Lollar P
• The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.
  Thromb Haemost Volume: 102 Page(s): 35 - 41
  07/01/2009 Authors: Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
• Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.
  J Thromb Haemost Volume: 7 Page(s): 658 - 664
  04/01/2009 Authors: Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
• Development of a Novel Recombinant Factor VIII Product through Transgene Engineering and Lentiviral-Driven Expression
  Volume: 112 Page(s): 1055 - 1055
  11/16/2008 Authors: Kerstann KW; Lollar P; Spencer HT; Denning G; Baranyi L; Keefe R; Dropulic B; Doering CB
• Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.
  Blood Volume: 112 Page(s): 1151 - 1153
  08/15/2008 Authors: Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
• Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
  Blood Volume: 110 Page(s): 4234 - 4242
  12/15/2007 Authors: Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
• Enhanced anticoagulant activity of factor VIII inhibitors due to positive cooperativity between two classes of anti-factor VIII C2 antibodies
  Volume: 110 Page(s): 241A - 241A
  11/16/2007 Authors: Meeks SL; Healey JF; Barrow RT; Parker ET; Lollar P
• Non-classical anti-factor VIIIC2 domain inhibitors are present in the plasmas of most factor VIII inhibitor patients
  Volume: 110 Page(s): 242A - 242A
  11/16/2007 Authors: Meeks SL; Healey JF; Barrow RT; Parker ET; Lollar P
• Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.
  Biochemistry Volume: 46 Page(s): 9737 - 9742
  08/28/2007 Authors: Parker ET; Lollar P
• The humoral response to human factor VIII in hemophilia A mice.
  J Thromb Haemost Volume: 5 Page(s): 512 - 519
  03/01/2007 Authors: Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
• Identification of three non-overlapping epitopes in the C2 domain of factor VIII.
  Volume: 108 Page(s): 300A - 300A
  11/16/2006 Authors: Meeks S; Healey JF; Lollar JPS
• Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII.
  J Thromb Haemost Volume: 4 Page(s): 2223 - 2229
  10/01/2006 Authors: Barrow RT; Lollar P
• Hemophilia and immunology at the crossroads.
  J Thromb Haemost Volume: 4 Page(s): 2170 - 2171
  10/01/2006 Authors: Lollar P
• A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation.
  J Biol Chem Volume: 281 Page(s): 13922 - 13930
  05/19/2006 Authors: Parker ET; Doering CB; Lollar P
• Factor VIIIa decay due to A2 subunit dissociation is regulated by the A1 domain
  Volume: 106 Page(s): 296A - 296A
  11/16/2005 Authors: Parker ET; Doering CB; Lollar P
• High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.
  Blood Volume: 106 Page(s): 3415 - 3422
  11/15/2005 Authors: Hausl C; Ahmad RU; Sasgary M; Doering CB; Lollar P; Richter G; Schwarz HP; Turecek PL; Reipert BM
• Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor.
  J Thromb Haemost Volume: 3 Page(s): 1385 - 1391
  07/01/2005 Authors: Lollar P
• Inhibition of factor VIII-specific memory B cell responses by supra-physiological concentrations of factor VIII.
  Volume: 104 Page(s): 15A - 15A
  11/16/2004 Authors: Hausl C; Ahmad RU; Sasgary M; Doering CB; Lollar PS; Richter G; Schwarz HP; Turecek PL; Reipert BM
• Comparative immunogenicity of two forms of porcine factor VIII in cynomolgus monkeys.
  Volume: 104 Page(s): 841A - 841A
  11/16/2004 Authors: Bergman GE; Lollar P
• Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope.
  Blood Volume: 104 Page(s): 704 - 710
  08/01/2004 Authors: Parker ET; Healey JF; Barrow RT; Craddock HN; Lollar P
• Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
  J Thromb Haemost Volume: 2 Page(s): 1082 - 1095
  07/01/2004 Authors: Lollar P
• Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.
  J Thromb Haemost Volume: 2 Page(s): 605 - 611
  04/01/2004 Authors: Parker ET; Craddock HN; Barrow RT; Lollar P
• Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion.
  J Biol Chem Volume: 279 Page(s): 6546 - 6552
  02/20/2004 Authors: Doering CB; Healey JF; Parker ET; Barrow RT; Lollar P
• Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate : C in hemophilia a mice pre-sensitized to human factor VIII.
  Volume: 102 Page(s): 798A - 798A
  11/16/2003 Authors: Parker ET; Craddock HN; Barrow RT; Lollar P
• Mapping the humoral response to factor VIII using single human domain hybrid factor VIII molecules.
  Volume: 102 Page(s): 162A - 162A
  11/16/2003 Authors: Healey JF; Parker ET; Barrow RT; Bretton VS; Church WR; Lollar P
• Characterization of the decay differential between activated human and porcine factor VIII using hybrid human/porcine factor VIII molecules.
  Volume: 102 Page(s): 541A - 541A
  11/16/2003 Authors: Doering CB; Parker ET; Barrow RT; Lollar P
• The factor VIII assay problem: neither rhyme nor reason.
  J Thromb Haemost Volume: 1 Page(s): 2275 - 2279
  11/01/2003 Authors: Lollar P
• Decreased factor VIII levels during acetaminophen-induced murine fulminant hepatic failure.
  Blood Volume: 102 Page(s): 1743 - 1744
  09/01/2003 Authors: Doering CB; Parker ET; Nichols CE; Lollar P
• A quantitative measure of the efficacy of factor VIII in hemophilia A mice.
  Thromb Haemost Volume: 89 Page(s): 480 - 485
  03/01/2003 Authors: Parker ET; Lollar P
• Identification of porcine factor VIII sequences conferring high-level expression.
  Volume: 100 Page(s): 262A - 262A
  11/16/2002 Authors: Doering CB; Healey JF; Parker ET; Barrow RT; Lollar P
• High level expression of recombinant porcine coagulation factor VIII.
  J Biol Chem Volume: 277 Page(s): 38345 - 38349
  10/11/2002 Authors: Doering CB; Healey JF; Parker ET; Barrow RT; Lollar P
• Expression and characterization of recombinant murine factor VIII.
  Thromb Haemost Volume: 88 Page(s): 450 - 458
  09/01/2002 Authors: Doering C; Parker ET; Healey JF; Craddock HN; Barrow RT; Lollar P
• Molecular characterization of the immune response to factor VIII.
  Vox Sang Volume: 83 Suppl 1 Page(s): 403 - 408
  08/01/2002 Authors: Lollar P
• Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure.
  Blood Volume: 100 Page(s): 143 - 147
  07/01/2002 Authors: Doering CB; Josephson CD; Craddock HN; Lollar P
• Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII.
  Blood Volume: 99 Page(s): 2828 - 2834
  04/15/2002 Authors: van den Brink EN; Bril WS; Turenhout EAM; Zuurveld M; Bovenschen N; Peters M; Yee TT; Mertens K; Lewis DA; Ortel TL
• Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.
  Blood Volume: 99 Page(s): 457 - 462
  01/15/2002 Authors: Lin Y; Chang L; Solovey A; Healey JF; Lollar P; Hebbel RP
• Amino acid residues R2215, R2220, and F2196 contribute to the antigenicity of the human factor VIIIC2 domain toward inhibitory antibodies.
  BLOOD Volume: 98 Page(s): 531A - 531A
  11/16/2001 Authors: Barrow RT; Lollar P
• Reduction in the immunogenicity of human FVIII in hemophilia A mice by site-directed mutagenesis of the A2 epitope.
  BLOOD Volume: 98 Page(s): 826A - 826A
  11/16/2001 Authors: Parker ET; Craddock HN; Barrow RT; Healey JF; Lollar P
• Decreased factor VIII procoagulant activity and gene expression in murine fulminant hepatic failure.
  BLOOD Volume: 98 Page(s): 70B - 70B
  11/16/2001 Authors: Doering CB; Lollar P
• Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin.
  Biochemistry Volume: 40 Page(s): 8508 - 8513
  07/24/2001 Authors: Lian F; He L; Colwell NS; Lollar P; Tollefsen DM
• The fVIII inhibitor problem comes into focus
  BLOOD Volume: 98 Page(s): 1 - 1
  07/01/2001 Authors: Lollar P
• Optimal treatment regimens for patients with bleeding disorders.
  Volume: 7 Page(s): 313 - 320
  05/01/2001
• Mechanism of the immune response to human factor VIII in murine hemophilia A.
  Thromb Haemost Volume: 85 Page(s): 125 - 133
  01/01/2001 Authors: Wu H; Reding M; Qian J; Okita DK; Parker E; Lollar P; Hoyer LW; Conti-Fine BM
• Factor VIII inhibitors.
  Adv Exp Med Biol Volume: 489 Page(s): 65 - 73
  01/01/2001 Authors: Lollar P; Healey JF; Barrow RT; Parker ET
• Antigenicity of putative phospholipid membrane-binding residues in factor VIII.
  Blood Volume: 97 Page(s): 169 - 174
  01/01/2001 Authors: Barrow RT; Healey JF; Jacquemin MG; Saint-Remy JM; Lollar P
• Antigenicity of putative phospholipid membrane binding residues in factor VIII.
  BLOOD Volume: 96 Page(s): 532A - 533A
  11/16/2000 Authors: Barrow RT; Healey JF; Lollar P
• Anticoagulant effects of a monoclonal antibody against exosite II of thrombin.
  Volume: 96 Page(s): 636A - 637A
  11/16/2000 Authors: Tollefsen DM; Li H; Colwell NS; Lollar P; Lian FG
• Novel polymorphisms of the human coagulation factor IX (fIX) gene.
  BLOOD Volume: 96 Page(s): 640A - +
  11/16/2000 Authors: Howard TE; Meng XP; Patel RM; Iber JC; Duncan A; Lollar JS; Warren ST
• Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules.
  Haematologica Volume: 85 Page(s): 26 - 28
  10/01/2000 Authors: Lollar P
• Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
  Blood Volume: 95 Page(s): 564 - 568
  01/15/2000 Authors: Barrow RT; Healey JF; Gailani D; Scandella D; Lollar P
• Differential expression of factor VIII and von Willbebrand factor in murine tissues.
  BLOOD Volume: 94 Page(s): 453A - 453A
  11/15/1999 Authors: Do H; Miller BS; Lollar P
• Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
  BLOOD Volume: 94 Page(s): 454A - 454A
  11/15/1999 Authors: Lollar P; Barrow RT; Healey JF; Gailani D; Scandella D
• Characterization of factor VIII B-cell inhibitory epitopes.
  Thromb Haemost Volume: 82 Page(s): 505 - 508
  08/01/1999 Authors: Lollar P
• Expression of factor VIII by murine liver sinusoidal endothelial cells.
  J Biol Chem Volume: 274 Page(s): 19587 - 19592
  07/09/1999 Authors: Do H; Healey JF; Waller EK; Lollar P
• Expression of factor VIII by murine liver sinusoidal endothelial cells.
  FASEB JOURNAL Volume: 13 Page(s): A1496 - A1496
  04/23/1999 Authors: Do HV; Healey JF; Waller EK; Lollar P
• Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.
  Blood Volume: 92 Page(s): 3701 - 3709
  11/15/1998 Authors: Healey JF; Barrow RT; Tamim HM; Lubin IM; Shima M; Scandella D; Lollar P
• Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity.
  J Biol Chem Volume: 273 Page(s): 12089 - 12094
  05/15/1998 Authors: Chang J; Jin J; Lollar P; Bode W; Brandstetter H; Hamaguchi N; Straight DL; Stafford DW
• Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis.
  J Biol Chem Volume: 272 Page(s): 30191 - 30195
  11/28/1997 Authors: Lubin IM; Healey JF; Barrow RT; Scandella D; Lollar P
• Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation.
  Blood Volume: 90 Page(s): 1902 - 1910
  09/01/1997 Authors: Thompson AR; Murphy ME; Liu M; Saenko EL; Healey JF; Lollar P; Scandella D
• Subunit structure and function of porcine factor Xa-activated factor VIII.
  Biochemistry Volume: 36 Page(s): 9365 - 9373
  08/05/1997 Authors: Parker ET; Pohl J; Blackburn MN; Lollar P
• Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII.
  Thromb Haemost Volume: 78 Page(s): 647 - 651
  07/01/1997 Authors: Lollar P
• The cDNA and derived amino acid sequence of porcine factor VIII.
  Blood Volume: 88 Page(s): 4209 - 4214
  12/01/1996 Authors: Healey JF; Lubin IM; Lollar P
• Restricted anti-A2 domain factor VIII (FVIII) inhibitor in a mild hemophilia a (HA) patient with an Arg(593)Cys mutation.
  BLOOD Volume: 88 Page(s): 2615 - 2615
  11/15/1996 Authors: Thompson AR; Murphy MEP; Lollar P; Scandella D
• Expression of a recombinant hybrid human/porcine factor VIII molecule with reduced reactivity toward anti-C2 domain inhibitory antibodies.
  BLOOD Volume: 88 Page(s): 2613 - 2613
  11/15/1996 Authors: Healey JF; Scandella D; Lollar P
• Subunit structure of factor Xa-activated porcine factor VIII
  CIRCULATION Volume: 94 Page(s): 1269 - 1269
  10/15/1996 Authors: Parker ET; Blackburn MN; Lollar P
• Alanine scanning mutagenesis of the factor VIII A2 domain inhibitory epitope
  CIRCULATION Volume: 94 Page(s): 1567 - 1567
  10/15/1996 Authors: Lubin IM; Healey JF; Scandella D; Lollar P
• Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII.
  J Biol Chem Volume: 271 Page(s): 13882 - 13887
  06/07/1996 Authors: Esmon CT; Lollar P
• X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.
  Proc Natl Acad Sci U S A Volume: 92 Page(s): 9796 - 9800
  10/10/1995 Authors: Brandstetter H; Bauer M; Huber R; Lollar P; Bode W
• Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII.
  Blood Volume: 86 Page(s): 2183 - 2190
  09/15/1995 Authors: Koshihara K; Qian J; Lollar P; Hoyer LW
• Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.
  J Biol Chem Volume: 270 Page(s): 14505 - 14509
  06/16/1995 Authors: Healey JF; Lubin IM; Nakai H; Saenko EL; Hoyer LW; Scandella D; Lollar P
• Structure and function of Factor VIII.
  Adv Exp Med Biol Volume: 386 Page(s): 3 - 17
  01/01/1995 Authors: Lollar P
• RESIDUES 484-509 CONTAIN A MAJOR DETERMINANT OF THE INHIBITORY EPITOPE IN THE A2 DOMAIN OF HUMAN FACTOR-VIII
  BLOOD Volume: 84 Page(s): A240 - A240
  11/15/1994 Authors: HEALEY JF; LUBIN IM; SCANDELLA D; LOLLAR P
• PROPERTIES OF AFFINITY-PURIFIED ANTI-FACTOR-VIII ANTIBODIES FROM PATIENTS WITH FACTOR-VIII INHIBITORS
  BLOOD Volume: 84 Page(s): A59 - A59
  11/15/1994 Authors: NAKAI H; LOLLAR P; HEALY J; SCANDELLA D
• Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator.
  J Biol Chem Volume: 269 Page(s): 26796 - 26800
  10/28/1994 Authors: Barrow RT; Parker ET; Krishnaswamy S; Lollar P
• INHIBITION BY HEPARIN OF THE INTRINSIC PATHWAY FACTOR-X ACTIVATOR
  CIRCULATION Volume: 90 Page(s): 349 - 349
  10/01/1994 Authors: BARROW RT; PARKER ET; KRISHNASWAMY S; LOLLAR P
• Inhibition of human factor VIIIa by anti-A2 subunit antibodies.
  J Clin Invest Volume: 93 Page(s): 2497 - 2504
  06/01/1994 Authors: Lollar P; Parker ET; Curtis JE; Helgerson SL; Hoyer LW; Scott ME; Scandella D
• Mechanism-based isocoumarin inhibitors for blood coagulation serine proteases. Effect of the 7-substituent in 7-amino-4-chloro-3-(isothioureidoalkoxy)isocoumarins on inhibitory and anticoagulant potency.
  J Med Chem Volume: 37 Page(s): 1298 - 1306
  04/29/1994 Authors: Kam CM; Kerrigan JE; Plaskon RR; Duffy EJ; Lollar P; Suddath FL; Powers JC
• Elimination of a major inhibitor epitope in factor VIII.
  J Biol Chem Volume: 269 Page(s): 8639 - 8641
  03/25/1994 Authors: Lubin IM; Healey JF; Scandella D; Runge MS; Lollar P
• Isolation and characterization of thrombin-activated human factor VIII.
  J Biol Chem Volume: 269 Page(s): 6246 - 6251
  02/25/1994 Authors: Curtis JE; Helgerson SL; Parker ET; Lollar P
• Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex.
  J Biol Chem Volume: 269 Page(s): 593 - 598
  01/07/1994 Authors: Barrow RT; Healey JF; Lollar P
• INHIBITION OF HUMAN FACTOR-VIIIA BY ANTI-A2 SUBUNIT ANTIBODIES
  BLOOD Volume: 82 Page(s): A60 - A60
  11/15/1993 Authors: LOLLAR P; PARKER ET; CURTIS JE; HELGERSON SL; SCANDELLA D
• INHIBITION BY HEPARIN OF THROMBIN-CATALYZED ACTIVATION OF THE FACTOR-VIII VON-WILLEBRAND-FACTOR COMPLEX
  BLOOD Volume: 82 Page(s): A151 - A151
  11/15/1993 Authors: BARROW RT; HEALEY JF; LOLLAR P
• EXPRESSION OF A RECOMBINANT HYBRID HUMAN PORCINE FACTOR-VIII MOLECULE WITH ELIMINATION OF REACTIVITY TOWARD AN INHIBITORY ANTI-HUMAN A2 DOMAIN ANTIBODY
  BLOOD Volume: 82 Page(s): A60 - A60
  11/15/1993 Authors: LUBIN IM; HEALEY JF; LOLLAR P; SCANDELLA D; RUNGE MS
• IMMUNOBLOT CROSS-REACTIVITY OF FACTOR-VIII INHIBITORS WITH PORCINE FACTOR-VIII
  BLOOD Volume: 82 Page(s): A61 - A61
  11/15/1993 Authors: KOSHIHARA K; LOLLAR P; HOYER LW
• Factor VIII and factor VIIIa.
  Methods Enzymol Volume: 222 Page(s): 128 - 143
  01/01/1993 Authors: Lollar P; Fay PJ; Fass DN
• Coagulant properties of hybrid human/porcine factor VIII molecules.
  J Biol Chem Volume: 267 Page(s): 23652 - 23657
  11/25/1992 Authors: Lollar P; Parker ET; Fay PJ
• COAGULANT PROPERTIES OF HYBRID HUMAN PORCINE FACTOR-VIII MOLECULES
  CIRCULATION Volume: 86 Page(s): 685 - 685
  10/01/1992 Authors: LOLLAR P; PARKER ET; FAY PJ
• INHIBITION OF THROMBIN ACTIVATION OF FACTOR-VIII BY A SYNTHETIC PEPTIDE CORRESPONDING TO RESIDUES 1675-1686 IN FACTOR-VIII
  CIRCULATION Volume: 86 Page(s): 413 - 413
  10/01/1992 Authors: MARAGANORE JR; HEALEY JF; PARKER ET; LOLLAR P
• Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.
  J Biol Chem Volume: 267 Page(s): 17006 - 17011
  08/25/1992 Authors: Duffy EJ; Parker ET; Mutucumarana VP; Johnson AE; Lollar P
• The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study.
  J Biol Chem Volume: 267 Page(s): 17012 - 17021
  08/25/1992 Authors: Mutucumarana VP; Duffy EJ; Lollar P; Johnson AE
• Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor Xdes-143-191.
  J Biol Chem Volume: 267 Page(s): 7821 - 7827
  04/15/1992 Authors: Duffy EJ; Lollar P
• TOPOLOGY OF MEMBRANE-BOUND FACTOR-IXA AND ITS CONFORMATIONAL SENSITIVITY TO FACTOR-VIIIA
  FASEB JOURNAL Volume: 6 Page(s): A330 - A330
  01/01/1992 Authors: MUTUCUMARANA VP; DUFFY EJ; LOLLAR P; JOHNSON AE
• INTERACTION OF FACTOR-IXA AND FACTOR-VIIIA ON PHOSPHOLIPID-VESICLES
  FASEB JOURNAL Volume: 6 Page(s): A328 - A328
  01/01/1992 Authors: DUFFY EJ; PARKER ET; MUTUCUMARANA VP; JOHNSON AE; LOLLAR P
• Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.
  J Biol Chem Volume: 266 Page(s): 12481 - 12486
  07/05/1991 Authors: Lollar P; Parker ET
• STRUCTURE AND FUNCTION OF THROMBIN-ACTIVATED FACTOR-VIII
  THROMBOSIS AND HAEMOSTASIS Volume: 65 Page(s): 818 - 818
  06/05/1991 Authors: LOLLAR P
• STRUCTURAL BASIS FOR THE DECREASED PROCOAGULANT ACTIVITY OF HUMAN FACTOR-VIII COMPARED TO THE PORCINE HOMOLOG
  THROMBOSIS AND HAEMOSTASIS Volume: 65 Page(s): 658 - 658
  06/05/1991 Authors: LOLLAR P; PARKER ET
• The association of factor VIII with von Willebrand factor.
  Mayo Clin Proc Volume: 66 Page(s): 524 - 534
  05/01/1991 Authors: Lollar P
• von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain.
  J Biol Chem Volume: 265 Page(s): 17854 - 17858
  10/15/1990 Authors: Hill-Eubanks DC; Lollar P
• VONWILLEBRAND-FACTOR IS A COFACTOR FOR THE THROMBIN-CATALYZED CLEAVAGE OF THE FACTOR-VIII LIGHT CHAIN
  CIRCULATION Volume: 82 Page(s): 593 - 593
  10/01/1990 Authors: HILLEUBANKS DC; LOLLAR P
• VONWILLEBRAND-FACTOR IS A COFACTOR FOR THE THROMBIN-CATALYZED CLEAVAGE OF THE FACTOR-VIII LIGHT CHAIN
  ARTERIOSCLEROSIS Volume: 10 Page(s): A903 - A904
  09/01/1990 Authors: HILLEUBANKS DC; LOLLAR P
• Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.
  J Clin Invest Volume: 85 Page(s): 1983 - 1990
  06/01/1990 Authors: Mosesson MW; Fass DN; Lollar P; DiOrio JP; Parker CG; Knutson GJ; Hainfeld JF; Wall JS
• pH-dependent denaturation of thrombin-activated porcine factor VIII.
  J Biol Chem Volume: 265 Page(s): 1688 - 1692
  01/25/1990 Authors: Lollar P; Parker CG
• Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.
  Proc Natl Acad Sci U S A Volume: 86 Page(s): 6508 - 6512
  09/01/1989 Authors: Hill-Eubanks DC; Parker CG; Lollar P
• COMPARISON OF THE ULTRASTRUCTURE OF PORCINE FACTOR-VIII AND FACTOR-VIIIA
  THROMBOSIS AND HAEMOSTASIS Volume: 62 Page(s): 200 - 200
  08/19/1989 Authors: MOSESSON MW; FASS DN; LOLLAR P; DIORIO JP; KNUTSON GJ; HAINFELD JF; WALL JS
• Subunit structure of thrombin-activated porcine factor VIII.
  Biochemistry Volume: 28 Page(s): 666 - 674
  01/24/1989 Authors: Lollar P; Parker CG
• SUBUNIT SPECIFICITY OF THE ACTIVATION OF FACTOR-VIII VONWILLEBRAND-FACTOR COMPLEX BY THROMBIN
  ARTERIOSCLEROSIS Volume: 8 Page(s): A699 - A699
  09/01/1988 Authors: LOLLAR P; PARKER CG; HILLEUBANKS DC
• SUBUNIT STRUCTURE OF THROMBIN-ACTIVATED PORCINE FACTOR-VIII
  ARTERIOSCLEROSIS Volume: 8 Page(s): A666 - A667
  09/01/1988 Authors: LOLLAR P; PARKER CG
• ASSOCIATION OF THE FACTOR-VIII LIGHT CHAIN WITH VONWILLEBRAND-FACTOR
  ARTERIOSCLEROSIS Volume: 8 Page(s): A698 - A698
  09/01/1988 Authors: LOLLAR P; PARKER CG; HILLEUBANKS DC
• Association of the factor VIII light chain with von Willebrand factor.
  J Biol Chem Volume: 263 Page(s): 10451 - 10455
  07/25/1988 Authors: Lollar P; Hill-Eubanks DC; Parker CG
• KINETICS OF THE ASSOCIATION OF FACTOR-VIII WITH WILLEBRAND FACTOR
  BIOPHYSICAL JOURNAL Volume: 53 Page(s): A76 - A76
  02/01/1988 Authors: LOLLAR P; PARKER CG; KRISHNASWAMY S
• Molecular characterization of commercial porcine factor VIII concentrate.
  Blood Volume: 71 Page(s): 137 - 143
  01/01/1988 Authors: Lollar P; Parker CG; Tracy RP
• Stoichiometry of the porcine factor VIII-von Willebrand factor association.
  J Biol Chem Volume: 262 Page(s): 17572 - 17576
  12/25/1987 Authors: Lollar P; Parker CG
• Degradation of coagulation proteins by an enzyme from Malayan pit viper (Akistrodon rhodostoma) venom.
  Biochemistry Volume: 26 Page(s): 7627 - 7636
  12/01/1987 Authors: Lollar P; Parker CG; Kajenski PJ; Litwiller RD; Fass DN
• Heterogeneous, ideal associations at sedimentation equilibrium.
  Biophys Chem Volume: 28 Page(s): 245 - 251
  12/01/1987 Authors: Lollar P
• MACROMOLECULAR INTERACTIONS AT SEDIMENTATION EQUILIBRIUM
  FEDERATION PROCEEDINGS Volume: 46 Page(s): 2275 - 2275
  05/01/1987 Authors: LOLLAR P
• ISOLATION AND CHARACTERIZATION OF A PROTEOLYTIC-ENZYME FROM MALAYAN PIT VIPER VENOM
  CIRCULATION Volume: 74 Page(s): 410 - 410
  10/01/1986 Authors: LOLLAR P
• DEGRADATION OF FACTOR-IX BY AN ENZYME FROM MALAYAN PIT VIPER VENOM
  CIRCULATION Volume: 74 Page(s): 410 - 410
  10/01/1986 Authors: LOLLAR P; PARKER CG; FASS DN
• Activation of porcine factor VIII:C by thrombin and factor Xa.
  Biochemistry Volume: 24 Page(s): 8056 - 8064
  12/31/1985 Authors: Lollar P; Knutson GJ; Fass DN
• Isolation and characterization of native adult osteonectin.
  J Biol Chem Volume: 260 Page(s): 2728 - 2736
  03/10/1985 Authors: Romberg RW; Werness PG; Lollar P; Riggs BL; Mann KG
• Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone.
  Arch Biochem Biophys Volume: 233 Page(s): 438 - 446
  09/01/1984 Authors: Lollar P; Fass DN
• Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid.
  Blood Volume: 63 Page(s): 1303 - 1308
  06/01/1984 Authors: Lollar P; Knutson GJ; Fass DN
• Reaction of antithrombin III with thrombin bound to the vascular endothelium. Analysis in a recirculating perfused rabbit heart preparation.
  J Biol Chem Volume: 259 Page(s): 4335 - 4338
  04/10/1984 Authors: Lollar P; MacIntosh SC; Owen WG
• ACTIVATION OF PORCINE FACTOR-VIII-C BY THROMBIN AND FACTOR-XA
  CIRCULATION Volume: 70 Page(s): 199 - 199
  01/01/1984 Authors: LOLLAR P; KNUTSON GJ; FASS DN
• Thrombolytic therapy: controversial aspects.
  J Iowa Med Soc Volume: 72 Page(s): 294 - 296
  07/01/1982 Authors: Gaffy MM; Lollar P; Goldsmith J
• Interaction of thrombin with the vascular endothelium in a recirculating Langendorff rabbit heart preparation.
  Ann N Y Acad Sci Volume: 401 Page(s): 234 - 240
  01/01/1982 Authors: Lollar P; MacIntosh S; Owen WG
• INTERACTION OF THROMBIN WITH THE VASCULAR ENDOTHELIUM IN A RECIRCULATING LANGENDORFF RABBIT HEART PREPARATION
  CIRCULATION Volume: 66 Page(s): 53 - 53
  01/01/1982 Authors: LOLLAR P; HALE SM; OWEN WG
• Massive fatal pulmonary emboli with fibrinolytic therapy.
  Circulation Volume: 64 Page(s): 1068 - 1069
  11/01/1981 Authors: Goldsmith JC; Lollar P; Hoak JC
• Prostacyclin release from cultured and ex vivo bovine vascular endothelium. Studies with thrombin, arachidonic acid, and ionophore A23187.
  Lab Invest Volume: 45 Page(s): 191 - 197
  08/01/1981 Authors: Goldsmith JC; Jafvert CT; Lollar P; Owen WG; Hoak JC
• Active-site-dependent, thrombin-induced release of adenine nucleotides from cultured human endothelial cells.
  Ann N Y Acad Sci Volume: 370 Page(s): 51 - 56
  01/01/1981 Authors: Lollar P; Owen WG
• THROMBIN-INDUCED RELEASE OF ADENINE-NUCLEOTIDES FROM CULTURED HUMAN-ENDOTHELIAL CELLS
  THROMBOSIS AND HAEMOSTASIS Volume: 46 Page(s): 72 - 72
  01/01/1981 Authors: LOLLAR P; OWEN WG
• Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III.
  J Clin Invest Volume: 66 Page(s): 1222 - 1230
  12/01/1980 Authors: Lollar P; Owen WG
• Binding of thrombin to cultured human endothelial cells. Nonequilibrium aspects.
  J Biol Chem Volume: 255 Page(s): 10279 - 10283
  11/10/1980 Authors: Lollar P; Hoak JC; Owen WG
• Silicone syncope.
  N Engl J Med Volume: 303 Page(s): 817
  10/02/1980 Authors: Thomsen TA; Lollar P; Doloresco F
• Evidence that the effects of thrombin on arachidonate metabolism in cultured human endothelial cells are not mediated by a high affinity receptor.
  J Biol Chem Volume: 255 Page(s): 8031 - 8034
  09/10/1980 Authors: Lollar P; Owen WG
• CLEARANCE OF THROMBIN FROM THE CIRCULATION BY HIGH-AFFINITY BINDING-SITES ON ENDOTHELIUM - POSSIBLE ROLE IN THE INACTIVATION OF THROMBIN BY ANTI-THROMBIN-III
  CIRCULATION Volume: 62 Page(s): 278 - 278
  01/01/1980 Authors: LOLLAR P; OWEN WG
• BINDING OF THROMBIN TO CULTURED HUMAN-ENDOTHELIAL CELLS - NONEQUILIBRIUM ASPECTS
  CIRCULATION Volume: 62 Page(s): 98 - 98
  01/01/1980 Authors: LOLLAR P; HOAK JC; OWEN WG
• EVIDENCE FOR ENDOTHELIAL RECEPTOR-MEDIATED CLEARANCE OF THROMBIN
  CLINICAL RESEARCH Volume: 27 Page(s): A300 - A300
  01/01/1979 Authors: LOLLAR P; OWEN WG
• Blood pressures in children.
  Mo Med Volume: 73 Page(s): 263 - 264
  06/01/1976 Authors: deCastro FJ; Christianson S; Lollar P